GlassScriptPhysician profile
Michael W Archie
NPI 1871563353
$1,214.97
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $176 · 2022: $21.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $238.16 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $225.76 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $218.22 | 2019-2020 | |
| Amgen INC. | $160.80 | 2019-2020 | |
| Vifor Pharma, INC. | $126.20 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $85.64 | 2019-2020 | |
| Daiichi Sankyo INC. | $46.28 | 2019-2020 | |
| Shire North American Group INC | $38.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.50 | 2019 | |
| Medtronic, INC. | $21.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Archie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.